<DOC>
	<DOC>NCT00463762</DOC>
	<brief_summary>The primary objective is to collect data on treatment outcomes (clinical and microbiological cure), safety and tolerability of treatment with cefoperazone/sulbactam in patients with serious intra-abdominal and hepatobiliary infections in Slovakia.</brief_summary>
	<brief_title>Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Appendicitis</mesh_term>
	<mesh_term>Wound Infection</mesh_term>
	<mesh_term>Peritonitis</mesh_term>
	<mesh_term>Cholecystitis</mesh_term>
	<mesh_term>Acalculous Cholecystitis</mesh_term>
	<mesh_term>Abdominal Abscess</mesh_term>
	<mesh_term>Sulbactam</mesh_term>
	<mesh_term>Cefoperazone</mesh_term>
	<mesh_term>Sulperazone</mesh_term>
	<criteria>Male or female patient of age 18 years or older. Patient with intraabdominal/hepatobiliary infection.? Patients with known hypersensitivity to penicillins, cephalosporins, cefoperazone or to sulbactam.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>